The rapid rise of injectable weight loss medications has transformed how obesity is treated, but new research suggests that these treatments may carry previously underreported risks. While many people successfully use these drugs to manage their weight and improve their metabolic health, a growing body of evidence indicates a potential link to psychiatric side effects. The findings were published in Pharmaceuticals.
A detailed analysis of real-world data has highlighted that semaglutide, a common ingredient in popular weight loss injectables, is disproportionately associated with reports of depression and anxiety. This finding is particularly significant given the global surge in demand for these treatments among both adults and teenagers.
Natalie Buchwald, founder and clinical director of Manhattan Mental Health Counseling, suggests the psychological effects may run deeper than the medication itself. “What I watch for clinically is whether a client’s anxiety around semaglutide is about the medication itself or about the identity disruption underneath. Sometimes the anxiety is the body’s signal that the psychological work of inhabiting a different self has not yet happened.”
The research also identified a concerning trend regarding suicidal ideation, which appeared more frequently in reports from patients using semaglutide compared to other similar medications. These psychological symptoms often go undetected in standard clinical trials that primarily focus on physical side effects such as nausea or digestive issues.
In contrast, users of tirzepatide reported much higher rates of injection site reactions, including pain, bruising, and localised swelling. Dosing errors are another major issue, with many patients accidentally taking too much or too little of their prescribed dose, particularly with tirzepatide shortly after it became widely available. Liraglutide, an older medication in the same class, appears to have a comparatively lower risk profile regarding both mental health and administration issues.
Dr Susan McClanahan, PhD, co-Founder of SpringSource and clinical assistant professor of psychiatry at Northwestern University Feinberg School of Medicine, urges caution in interpreting the emerging evidence. “Current evidence is mixed. Some real-world data suggests increased reports of depression, anxiety, or suicidal thoughts, while larger clinical and observational studies have not established a clear causal relationship. Importantly, individuals seeking weight-related care often have higher baseline rates of mood disorders and eating disorders, which are frequently under-recognised, particularly in higher-weight patients.”
Misuse of these medications is also a growing public health concern, with many individuals obtaining them from unregulated online sources for cosmetic purposes without appropriate medical supervision.
Medical professionals are being encouraged to screen patients for a history of depression or anxiety before starting treatment. Dr McClanahan adds that sustainable outcomes require more than medication alone. “These treatments can produce rapid physical changes, while identity, coping strategies, and relationships with food evolve more slowly. Medication is a powerful tool, but not a complete treatment model.”
Regulatory oversight may also need to be strengthened to prevent inappropriate use among those who do not meet the clinical criteria for treatment.
